The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Description

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

Conditions

Pre-diabetes, Obesity

Study Overview

Study Details

Study overview

The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Condition
Pre-diabetes
Intervention / Treatment

-

Contacts and Locations

Lexington

University of Kentucky, Lexington, Kentucky, United States, 40536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Hemoglobin A1C between 5.7 and 6.4
  • * Body mass index between 27 and 45
  • * Diabetes
  • * Chronic use of any antidiabetic medications
  • * Any unstable medical condition
  • * Use of steroids or daily use of NSAIDS
  • * History of chronic inflammatory conditions
  • * Use of anticoagulants
  • * Contraindications to the use of mirabegron or tadalafil
  • * Any condition deemed risky by the study physician

Ages Eligible for Study

35 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Philip Kern,

Philip Kern, M.D., PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2025-02-28